Akcea Therapeutics Files Registration Statement for Proposed Initial Public Offering

CAMBRIDGE, Mass., March 27, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not been determined. Akcea has applied to list its common stock on the Nasdaq Global Market under the trading symbol "AKCA."

Cowen and Company, Stifel and Wells Fargo Securities are acting as joint book running managers for the offering.

The proposed offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by telephone at [phone]; or from Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at [phone], or by email at [e-mail]; or from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, NY 10152, or by telephone at [phone], or by email at [e-mail].

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/akcea-therapeutics-files-registration-statement-for-proposed-initial-public-offering-300429489.html

SOURCE Ionis Pharmaceuticals, Inc.

Copyright 2017 PR Newswire